Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Quick Ratio: 23.74 (As of Dec. 2025) — 37% Above Median


ROCO:7427 Great Novel Therapeutics Biotech & Medicals ROCO:7427
49 GF Score
Price NT$42.25
GF Value NT$25.66
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Great Novel Therapeutics Biotech & Medicals Quick Ratio?

Great Novel Therapeutics Biotech & Medicals ROCO:7427 +6.29% 49 Quick Ratio is 23.74 as of Dec. 2025, which is 37% above its 10-year median of 17.37. GuruFocus rates ROCO:7427 with a GF Score™ of 49/100 and a GF Value™ of NT$25.66 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,409 Biotechnology companies, Great Novel Therapeutics Biotech & Medicals ranks better than 94.82% on this metric.

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Great Novel Therapeutics Biotech & Medicals's quick ratio for the quarter that ended in Dec. 2025 was 23.74.

Great Novel Therapeutics Biotech & Medicals has a quick ratio of 23.74. It generally indicates good short-term financial strength.

The historical rank and industry rank for Great Novel Therapeutics Biotech & Medicals's Quick Ratio or its related term are showing as below:

ROCO:7427' s Quick Ratio Range Over the Past 10 Years
Min: 2.22   Med: 17.37   Max: 30.08
Current: 23.74

During the past 8 years, Great Novel Therapeutics Biotech & Medicals's highest Quick Ratio was 30.08. The lowest was 2.22. And the median was 17.37.

ROCO:7427's Quick Ratio is ranked better than
94.82% of 1409 companies
in the Biotechnology industry
Industry Median: 3.6 vs ROCO:7427: 23.74

Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Great Novel Therapeutics Biotech & Medicals Quick Ratio Related Terms


Great Novel Therapeutics Biotech & Medicals Quick Ratio Historical Data

* Premium members only.

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Great Novel Therapeutics Biotech & Medicals Quick Ratio Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Quick Ratio
Get a 7-Day Free Trial 5.80 20.87 30.08 27.30 23.74

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.08 29.77 27.30 30.15 23.74

ROCO:7427 vs VRTX, REGN, ALNY: Quick Ratio Comparison

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Great Novel Therapeutics Biotech & Medicals Quick Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's Quick Ratio falls into.


ROCO:7427
49GF Score
Great Novel Therapeutics Biotech & Medicals ROCO:7427
Quick Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Great Novel Therapeutics Biotech & Medicals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Great Novel Therapeutics Biotech & Medicals's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Quick Ratio (A: Dec. 2025 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(466.451-7.295)/19.337
=23.74

Great Novel Therapeutics Biotech & Medicals's Quick Ratio for the quarter that ended in Dec. 2025 is calculated as

Quick Ratio (Q: Dec. 2025 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(466.451-7.295)/19.337
=23.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Quick Ratio →
What does a Quick Ratio of 23.74 mean?
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) has a Quick Ratio of 23.74 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. This is 37% above median its historical median of 17.37. Over the past decade, Great Novel Therapeutics Biotech & Medicals' Quick Ratio has ranged from 2.22 to 30.08. According to the industry distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #73 out of 1409 companies in the Biotechnology industry, placing it in the top 5.2%.
Is Great Novel Therapeutics Biotech & Medicals' Quick Ratio too high?
Great Novel Therapeutics Biotech & Medicals' current Quick Ratio of 23.74 is 37% above median its 10-year median of 17.37. Over the past 10 years, this metric has ranged from a low of 2.22 to a high of 30.08. The Biotechnology industry median Quick Ratio is 3.60. Great Novel Therapeutics Biotech & Medicals' value of 23.74 is 559.4% above this industry median. Based on the distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #73 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Great Novel Therapeutics Biotech & Medicals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Great Novel Therapeutics Biotech & Medicals' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #73 out of 1409 companies for Quick Ratio. This places Great Novel Therapeutics Biotech & Medicals in the top 5% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Great Novel Therapeutics Biotech & Medicals' value of 23.74 is 559.4% above this benchmark. Historically, Great Novel Therapeutics Biotech & Medicals' own Quick Ratio has ranged from 2.22 to 30.08 over the past decade. While the company's 10-year median is 17.37 vs. the industry median of 3.60, Great Novel Therapeutics Biotech & Medicals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Great Novel Therapeutics Biotech & Medicals's current Quick Ratio of 23.74 is 559.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Great Novel Therapeutics Biotech & Medicals's current Quick Ratio is 23.74, which is 37% above median its own 10-year median of 17.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals (ROCO:7427) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.66, compared to a current price of NT$42.25 — trading 64.7% above its estimated fair value. The current Quick Ratio is 23.74, which is 37% above median its 10-year median of 17.37 and 559.4% above the Biotechnology industry median of 3.60. Great Novel Therapeutics Biotech & Medicals' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Great Novel Therapeutics Biotech & Medicals (ROCO:7427), the current Quick Ratio is 23.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?

Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be overvalued. The current stock price of NT$42.25 is trading 64.7% above its estimated GF Value™ of NT$25.66. GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Significantly Overvalued.

Key valuation signals for ROCO:7427:

  • Quick Ratio: 23.74 (37% above median its 10-year median of 17.37)
  • GF Value™: NT$25.66 vs. price of NT$42.25 (64.7% above fair value)
  • GF Score™: 49/100 with 6 warning signs
  • Industry Position: 559.4% above the Biotechnology median (#73 of 1409)

No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Great Novel Therapeutics Biotech & Medicals Business Description

Address No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
49GF Score

Get the complete analysis for ROCO:7427

Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$42.25
Price
NT$25.66
GF Value